mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

NCT01486992 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Advanced Esophageal Carcinoma

Interventions

DRUG: mFOLFIRI+Nimotuzumab

Sponsor

Peking University